| Myasthenia Gravis, Generalized
Bkemv vs Vyvgart Hytrulo
Side-by-side clinical, coverage, and cost comparison for myasthenia gravis, generalized.Deep comparison between: Bkemv vs Vyvgart Hytrulo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVyvgart Hytrulo has a higher rate of injection site reactions vs Bkemv based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vyvgart Hytrulo but not Bkemv, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Bkemv
Vyvgart Hytrulo
At A Glance
IV infusion
Every 2 weeks
Complement C5 inhibitor
SC injection
Once weekly
FcRn blocker
Indications
- Paroxysmal nocturnal hemoglobinuria
- Atypical Hemolytic Uremic Syndrome
- Myasthenia Gravis, Generalized
- Myasthenia Gravis, Generalized
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Dosing
Paroxysmal nocturnal hemoglobinuria 600 mg IV weekly for 4 weeks, then 900 mg at week 5, then 900 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized 900 mg IV weekly for 4 weeks, then 1,200 mg at week 5, then 1,200 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome (pediatric, <18 years) Weight-based IV dosing: induction 300-900 mg and maintenance 300-1,200 mg every 2-3 weeks depending on body weight (5 kg and over).
Myasthenia Gravis, Generalized 1,000 mg efgartigimod alfa/10,000 units hyaluronidase SC once weekly for 4-week cycles (prefilled syringe over 20-30 seconds) or 1,008 mg/11,200 units (vial over 30-90 seconds); subsequent cycles based on clinical evaluation.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1,000 mg efgartigimod alfa/10,000 units hyaluronidase SC once weekly (prefilled syringe over 20-30 seconds) or 1,008 mg/11,200 units (vial over 30-90 seconds); continue based on clinical response.
Contraindications
- Unresolved serious Neisseria meningitidis infection
- Serious hypersensitivity to efgartigimod alfa products, hyaluronidase, or any excipient of VYVGART HYTRULO (including anaphylaxis and hypotension leading to syncope)
Adverse Reactions
Most common (>=5%) Headache, nasopharyngitis, back pain, nausea, fatigue, cough, herpes simplex infections, musculoskeletal pain, hypertension, diarrhea, vomiting, pyrexia, peripheral edema.
Serious Meningococcal infections, other serious infections, thrombosis, infusion-related reactions, disease manifestation exacerbation after discontinuation.
Postmarketing Fatal or serious infections (Neisseria gonorrhoeae, Neisseria meningitidis, Neisseria species), cholestatic or mixed pattern liver injury with elevated liver enzymes and bilirubin.
Most common (>=10%) Injection site reactions (rash, erythema, pruritus, bruising, pain, urticaria), headache
Serious Infections, hypersensitivity reactions (including anaphylaxis and hypotension), infusion/injection-related reactions
Postmarketing Hypersensitivity reactions including anaphylaxis and hypotension, infusion/injection-related reactions, worsening of CIDP symptoms when transitioning from intravenous immunoglobulin treatment
Pharmacology
Complement C5 inhibitor; eculizumab-aeeb is a recombinant humanized monoclonal IgG2/4kappa antibody that specifically binds complement protein C5 with high affinity, inhibiting its cleavage to C5a and C5b and preventing generation of the terminal complement complex C5b-9, thereby inhibiting terminal complement-mediated intravascular hemolysis in PNH and complement-mediated thrombotic microangiopathy in aHUS.
Efgartigimod alfa, a human IgG1 Fc fragment, binds to the neonatal Fc receptor (FcRn) and reduces circulating IgG; co-formulated hyaluronidase transiently depolymerizes hyaluronan to increase subcutaneous tissue permeability for 24 to 48 hours.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bkemv
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
Vyvgart Hytrulo
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Bkemv
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Vyvgart Hytrulo
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Humana
Bkemv
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Vyvgart Hytrulo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Bkemv.
No savings programs available for Vyvgart Hytrulo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Vyvgart HytruloView full Vyvgart Hytrulo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.